Targeted therapy of ESBL infections and other resistant gram negative infections
Empiric therapy when broad spectrum of carbapenems is desired without the need for anti-pseudomonal activity
No published human data.
No teratogenicity was observed in animal studies.
There is no evidence that any beta-lactam antibiotic causes developmental toxicity in humans at therapeutic doses, therefore, if ertapenem is required by the mother, benefit outweighs the unknown risks.
Immediate and delayed-type allergy
Cytopenias, eosinophilia, positive Coombs
Liver enzyme abnormalities
Seizure risk lower than other carbapenems
Antimicrobial class: Carbapenem